[18F]FLT PET for Non-Invasive Monitoring of Early Response to Gene Therapy in Experimental Gliomas

[1]  Klaus Wienhard,et al.  Glioma Proliferation as Assessed by 3‘-Fluoro-3’-Deoxy-l-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma , 2008, Clinical Cancer Research.

[2]  Valerie A Longo,et al.  Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3′-Deoxy-3′-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas , 2008, Journal of Nuclear Medicine.

[3]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Karl Herholz,et al.  18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[8]  J. Barrio,et al.  Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography , 2005, Cancer Gene Therapy.

[9]  P. Box.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .

[10]  Michael E Phelps,et al.  Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Jae Seung Kim,et al.  [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Rainer Schrader,et al.  Fast and robust registration of PET and MR images of human brain , 2004, NeuroImage.

[13]  H. Hoekstra,et al.  3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  K. Krohn,et al.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[16]  D. Visvikis,et al.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  W. Heiss,et al.  Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. , 2003, Human gene therapy.

[18]  W. Heiss,et al.  Molecular Imaging of Gliomas , 2002, Molecular imaging.

[19]  H. Dittmann,et al.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  A. Belldegrun,et al.  CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. , 2002, The Journal of urology.

[21]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[23]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[24]  W. K. Alfred Yung.  PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .

[25]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[26]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[27]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[28]  U. Haberkorn,et al.  Synthesis of 3′‐deoxy‐3′‐[18F]fluoro‐thymidine with 2,3′‐anhydro‐5′‐O‐(4,4′‐dimethoxytrityl)‐thymidine , 2000 .

[29]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[30]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[31]  R. Grossman,et al.  Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  J. R. Grierson,et al.  Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .

[33]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[34]  L. Mariani,et al.  A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir , 1999 .

[35]  L. Mariani,et al.  A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. , 1999, Human gene therapy.

[36]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[37]  G. Brix,et al.  Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase , 1998, Gene Therapy.

[38]  M. Black,et al.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Wintersberger,et al.  Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.

[40]  T. Chou,et al.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[41]  K Wienhard,et al.  Validity of PET studies in brain tumors. , 1990, Cerebrovascular and brain metabolism reviews.